Final oocyte maturation with two different GnRH agonists in antagonist co-treated cycles at risk of ovarian hyperstimulation syndrome

Abstract Triptorelin 0.2 mg and leuprolide 1 mg subcutaneous injections for triggering final follicular maturation were compared in patients with a high risk for ovarian hyperstimulation syndrome (OHSS). Infertile patients treated with GnRH antagonist protocol between January 2014 and March 2016 wer...

Full description

Saved in:
Bibliographic Details
Published in:Reproductive biomedicine online 2017-01, Vol.34 (1), p.5-10
Main Authors: Şükür, Yavuz Emre, Özmen, Batuhan, Özdemir, Elif Didem, Seval, Mehmet Murat, Kalafat, Erkan, Sönmezer, Murat, Berker, Bülent, Aytaç, Ruşen, Atabekoğlu, Cem Somer
Format: Article
Language:English
Subjects:
Adolescent
Adult
Estradiol - blood
Female
GnRH agonist trigger
GnRH antagonist
Gonadotropin-Releasing Hormone - agonists
Gonadotropin-Releasing Hormone - antagonists & inhibitors
Hormone Antagonists - therapeutic use
Humans
Infertility, Female - therapy
Infertility, Male - therapy
intracytoplasmic sperm injection
leuprolide
Leuprolide - administration & dosage
Male
Obstetrics and Gynecology
Oocytes - cytology
Oocytes - drug effects
Oogenesis
Ovarian Hyperstimulation Syndrome - drug therapy
Ovulation Induction
Pregnancy
Pregnancy Rate
Retrospective Studies
Risk
Sperm Injections, Intracytoplasmic
triptorelin
Triptorelin Pamoate - administration & dosage
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Triptorelin 0.2 mg and leuprolide 1 mg subcutaneous injections for triggering final follicular maturation were compared in patients with a high risk for ovarian hyperstimulation syndrome (OHSS). Infertile patients treated with GnRH antagonist protocol between January 2014 and March 2016 were recruited. Patients with high serum oestradiol levels on HCG day (>3000 pg/ml) indicating a risk of OHSS consisted of the study groups (A and B). Patients with serum oestradiol levels less than 3000 pg/ml consisted of the control group (C). A single injection of 0.2 mg triptorelin, 1 mg leuprolide and 10000 IU HCG were administered for final oocyte triggering in groups A ( n = 63), B ( n = 74) and C ( n = 131), respectively. Demographic parameters were comparable between the groups. No cases of severe or moderate OHSS occurred in any group. The clinical pregnancy rates were 31.7%, 37.8% and 32.8% in groups A, B and C, respectively. Both injections had comparable efficacy in clinical outcome and OHSS risk. Regardless of preferred drug, GnRH agonist trigger for final oocyte maturation seems to be safe for patients with high OHSS risk, and can be safely used in fresh embryo transfer cycles.
ISSN:1472-6483
1472-6491
DOI:10.1016/j.rbmo.2016.10.004